• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Captopril mitigates radiation-induced lung fibrosis in rats

byKhang DinhandAndrew Bishara
May 30, 2014
in Oncology
Reading Time: 3 mins read
Ambrisentan found ineffective against idiopathic pulmonary fibrosis
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. Captopril or the synthetic antioxidant, EUK-207, reduced functional, biochemical, and histopathological signs of lung fibrosis after whole thoracic radiation.

2. The combination of captopril and EUK-207 was incrementally superior at reducing fibrosis than either agent alone.

Evidence rating: 2 (Good)

Study Rundown: Radiation therapy is a mainstay in the treatment of lung cancer. Despite advances in technologies that have allowed radiation to be more precisely directed at tumors, normal lung tissue is also unavoidably irradiated. The result is inflammation and fibrosis that may lead to pneumonitis, which can be lethal. It has been shown that both antioxidants and angiotensin converting enzyme (ACE) inhibitors mitigate collateral toxicity to normal lung. In this study, the authors show that the synthetic antioxidant EUK-207 and captopril are effective in reducing functional, biochemical, and histopathological indicators of inflammation and fibrosis in rats that were irradiated. This study was limited by its short endpoint of 32 weeks. The authors also selected a species of rats that are especially prone to radiation-induced fibrosis, which may have biased the results to improvement with any agent. There was also no pharmacological control group.

Click to read the study in International Journal of Radiation Oncology

RELATED REPORTS

Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy 

#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH

Relevant reading: Radiation damage to the lung: Mitigation by angiotensin-converting enzyme (ACE) inhibitors

In Depth [Basic Science Study]: In this study, female SD rats were separated into six groups, consisting of eight rats each: untreated control, WTR alone, WTR and EUK-207, WTR and captopril, WTR and captopril plus EUK-207, or EUK-207 plus captopril without radiation. 11 Gy of radiation was delivered using an image-guided animal irradiator. From one week to 14 weeks post-irradiation, rats were treated according to their group design and then sacrificed at 32 weeks. Inflammation was estimated with 8-hydroxy-2-deoxyguanosine staining (8-OHdG), malonidaldehyde levels (MDA), and macrophage activation (ED-1). TGF-beta staining and hydroxyproline levels were used as proxy measures of fibrosis. At 32 weeks, the breathing rate for the WTR group and WTR + captopril plus EUK-207 group was 200 and 150, respectively (P<0.01). The relative expression of 8-OHdG for WTR group and WTR + captopril plus EUK-207 group were 15 and 7.3, respectively (P<0.01); MDA levels were 11 and 3, respectively (P<0.01); ED-1 were 7.5 and 4, respectively. Similarly, hydroxyproline levels for WTR group and WTR + captopril plus EUK-207 group were 160ug and 70ug, respectively (P<0.01), while TGF-beta relative expression was 43 and 10, respectively (P<0.01). For 8-OHdG and ED-1, the combined treatment group was superior to single therapy alone. Statistical analysis was performed using ANOVA and Tukey method of least-square means.

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, Radiosurgery alone may be effective for some arteriovenous malformations, Escalated-dose radiotherapy did not increase survival in prostate cancer, Stereotactic radiosurgery promising for patients with multiple brain metastases

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: antioxidantbasic science studycaptoprilfibrosislung radiationRadiation Oncologyrats
Previous Post

H1N1 vaccine likely safe for pregnant mothers

Next Post

Chemoembolization comparable to standard-of-care for small hepatocellular cancers

RelatedReports

Cardiology

Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy 

October 15, 2024
#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH
StudyGraphics

#VisualAbstract: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Liver Fibrosis was More Effective Than Placebo at Resolving MASH

June 19, 2024
Radiation therapy collage: an older woman in a calm portrait beside the curved arm of a treatment machine and a mesh mask
Oncology

Prophylactic Radiation Therapy for High-Risk Asymptomatic Bone Metastases

October 2, 2023
Chronic Disease

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

September 20, 2023
Next Post

Chemoembolization comparable to standard-of-care for small hepatocellular cancers

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Overall improvement in management of high blood pressure between 1994 and 2011

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind November 2, 2026
  • Early mitral valve surgery may improve long-term survival in asymptomatic severe mitral regurgitation
  • CDC reports increasing early-season influenza activity and at least 900 deaths nationwide
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.